Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...

NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ:VKTX). Such investors are ...

There are no important events for this country at this time. Select "All" to see top events in other countries or view all events.

SAN DIEGO—Matthew Singleton, a director at Viking Therapeutics, Inc. (NASDAQ:VKTX), recently executed a significant stock sale, according to a filing with the Securities and... ByInvesting.com ...

Gainers: EKSO +22%. NDRM +13%. AEMD +9%. ALXN +8%. CRVS +7%.Losers: ATNM -17%. VKTX -11%. APTO -10%. ALDX -10%. RGLS -9%.Now read: Alexion: Suspicions Of Improper ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

When it comes to pre-revenue biotechs, it's often a struggle to build an investment thesis beyond "if the medicine works, the ...

Following Trump's election victory, investors responded Wednesday by pouring a lot of money into exchange-traded funds. In this week's ETF Wrap, Christine Idzelis broke down the money flows and the ...

Viking Therapeutics (NASDAQ: VKTX) soared to center stage earlier this year as a potentially promising player in one of today's highest-growth healthcare markets: weight loss drugs. The biotech ...

Viking Therapeutics (VKTX) is up more than +5% after the company’s experimental pill, VK2735, showed weight loss in patients at higher doses with limited side effects. Air Transport Services Group ...

And while that proposition is certainly true with Viking Therapeutics, (NASDAQ: VKTX) there's more than one reason for why the stock is worth buying. In fact, there are at least four arguments ...

A new stronger Ozempic is coming. Here’s what to knowNovo Nordisk (NVO) teased some new details about a potential Ozempic ...